SAGE Therapeutics (NASDAQ:SAGE) released its earnings results on Tuesday. The biopharmaceutical company reported ($3.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.41) by ($0.07), Fidelity Earnings reports. The business had revenue of $3.57 million during the quarter, compared to analyst estimates of $2.52 million. During the same quarter last year, the business earned ($2.63) earnings per share. The company’s quarterly revenue was up 35600.0% on a year-over-year basis.
Shares of NASDAQ:SAGE traded down $1.56 during midday trading on Thursday, reaching $142.49. 1,526 shares of the company’s stock traded hands, compared to its average volume of 362,067. The company has a market cap of $7.46 billion, a price-to-earnings ratio of -17.83 and a beta of 2.49. The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.00 and a current ratio of 16.00. SAGE Therapeutics has a one year low of $79.88 and a one year high of $193.56. The stock has a 50 day moving average of $142.22 and a 200 day moving average of $163.73.
Several equities research analysts have commented on the company. BidaskClub downgraded SAGE Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, November 1st. William Blair reissued a “buy” rating on shares of SAGE Therapeutics in a report on Wednesday, July 24th. JPMorgan Chase & Co. reissued a “buy” rating on shares of SAGE Therapeutics in a report on Wednesday, July 24th. Oppenheimer dropped their target price on SAGE Therapeutics from $200.00 to $190.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Finally, Canaccord Genuity dropped their target price on SAGE Therapeutics from $220.00 to $218.00 and set a “buy” rating on the stock in a report on Wednesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $201.00.
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).
Further Reading: Cost of Equity For A Business, Investors
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.